Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 46 of 46 entries
Sorted by: Best Match Show Resources per page
Differences in Inflammation, Treatment and Outcomes between Black and non-Black Patients Hospitalized for COVID-19: A Prospective Cohort Study.

The American journal of medicine

Azam TU, Berlin H, Anderson E, Pan M, Shadid HR, Padalia K, O'Hayer P, Meloche C, Feroze R, Michaud E, Launius C, Blakely P, Bitar A, Willer C, Pop-Busui R, Carethers JM, Hayek SS.
PMID: 34793753
Am J Med. 2021 Nov 15; doi: 10.1016/j.amjmed.2021.10.026. Epub 2021 Nov 15.

PURPOSE: Racial disparities in COVID-19 outcomes have been described. We sought to determine whether differences in inflammatory markers, use of COVID-19 therapies, enrollment in clinical trials, and in-hospital outcomes contribute to racial disparities between Black and non-Black patients hospitalized...

Cite
Azam TU, Berlin H, Anderson E, et al. Differences in Inflammation, Treatment and Outcomes between Black and non-Black Patients Hospitalized for COVID-19: A Prospective Cohort Study. Am J Med. 2021;doi: 10.1016/j.amjmed.2021.10.026.
Azam, T. U., Berlin, H., Anderson, E., Pan, M., Shadid, H. R., Padalia, K., O'Hayer, P., Meloche, C., Feroze, R., Michaud, E., Launius, C., Blakely, P., Bitar, A., Willer, C., Pop-Busui, R., Carethers, J. M., & Hayek, S. S. (2021). Differences in Inflammation, Treatment and Outcomes between Black and non-Black Patients Hospitalized for COVID-19: A Prospective Cohort Study. The American journal of medicine, . https://doi.org/10.1016/j.amjmed.2021.10.026
Azam, Tariq U, et al. "Differences in Inflammation, Treatment and Outcomes between Black and non-Black Patients Hospitalized for COVID-19: A Prospective Cohort Study." The American journal of medicine vol. (2021). doi: https://doi.org/10.1016/j.amjmed.2021.10.026
Azam TU, Berlin H, Anderson E, Pan M, Shadid HR, Padalia K, O'Hayer P, Meloche C, Feroze R, Michaud E, Launius C, Blakely P, Bitar A, Willer C, Pop-Busui R, Carethers JM, Hayek SS. Differences in Inflammation, Treatment and Outcomes between Black and non-Black Patients Hospitalized for COVID-19: A Prospective Cohort Study. Am J Med. 2021 Nov 15; doi: 10.1016/j.amjmed.2021.10.026. Epub 2021 Nov 15. PMID: 34793753; PMCID: PMC8592847.
Copy Download .nbib Format: NLM
Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients.

Journal of diabetes investigation

Pop-Busui R, Backlund JC, Bebu I, Braffett BH, Lorenzi G, White NH, Lachin JM, Soliman EZ.
PMID: 34309223
J Diabetes Investig. 2021 Jul 26; doi: 10.1111/jdi.13635. Epub 2021 Jul 26.

AIMS/INTRODUCTION: Cardiovascular autonomic neuropathy (CAN) is a predictor of cardiovascular disease and mortality. Cardiovascular reflex tests (CARTs) are the gold standard for the diagnosis of CAN, but might not be feasible in large research cohorts or in clinical care....

Cite
Pop-Busui R, Backlund JC, Bebu I, et al. Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients. J Diabetes Investig. 2021;doi: 10.1111/jdi.13635.
Pop-Busui, R., Backlund, J. C., Bebu, I., Braffett, B. H., Lorenzi, G., White, N. H., Lachin, J. M., Soliman, E. Z. (2021). Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients. Journal of diabetes investigation, . https://doi.org/10.1111/jdi.13635
Pop-Busui, Rodica, et al. "Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients." Journal of diabetes investigation vol. (2021). doi: https://doi.org/10.1111/jdi.13635
Pop-Busui R, Backlund JC, Bebu I, Braffett BH, Lorenzi G, White NH, Lachin JM, Soliman EZ. Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients. J Diabetes Investig. 2021 Jul 26; doi: 10.1111/jdi.13635. Epub 2021 Jul 26. PMID: 34309223.
Copy Download .nbib Format: NLM
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.

Circulation

Nelson AJ, Pagidipati NJ, Aroda VR, Cavender MA, Green JB, Lopes RD, Al-Khalidi H, Gaynor T, Kaltenbach LA, Kirk JK, Lingvay I, Magwire ML, O'Brien EC, Pak J, Pop-Busui R, Richardson CR, Reed M, Senyucel C, Webb L, McGuire DK, Granger CB.
PMID: 34228476
Circulation. 2021 Jul 06;144(1):74-84. doi: 10.1161/CIRCULATIONAHA.121.053766. Epub 2021 Jul 06.

Multiple sodium glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to impart significant cardiovascular and kidney benefits, but are underused in clinical practice. Both SGLT-2i and GLP-1RA were first studied as glucose-lowering drugs, which...

Cite
Nelson AJ, Pagidipati NJ, Aroda VR, et al. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation. 2021;144(1):74-84doi: 10.1161/CIRCULATIONAHA.121.053766.
Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lopes, R. D., Al-Khalidi, H., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., Lingvay, I., Magwire, M. L., O'Brien, E. C., Pak, J., Pop-Busui, R., Richardson, C. R., Reed, M., Senyucel, C., Webb, L., McGuire, D. K., & Granger, C. B. (2021). Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation, 144(1), 74-84. https://doi.org/10.1161/CIRCULATIONAHA.121.053766
Nelson, Adam J, et al. "Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community." Circulation vol. 144,1 (2021): 74-84. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.053766
Nelson AJ, Pagidipati NJ, Aroda VR, Cavender MA, Green JB, Lopes RD, Al-Khalidi H, Gaynor T, Kaltenbach LA, Kirk JK, Lingvay I, Magwire ML, O'Brien EC, Pak J, Pop-Busui R, Richardson CR, Reed M, Senyucel C, Webb L, McGuire DK, Granger CB. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation. 2021 Jul 06;144(1):74-84. doi: 10.1161/CIRCULATIONAHA.121.053766. Epub 2021 Jul 06. PMID: 34228476.
Copy Download .nbib Format: NLM
Diabetes and obesity are the main metabolic drivers of peripheral neuropathy.

Annals of clinical and translational neurology

Callaghan BC, Gao L, Li Y, Zhou X, Reynolds E, Banerjee M, Pop-Busui R, Feldman EL, Ji L.
PMID: 29687018
Ann Clin Transl Neurol. 2018 Feb 14;5(4):397-405. doi: 10.1002/acn3.531. eCollection 2018 Apr.

OBJECTIVE: To determine the associations between individual metabolic syndrome (MetS) components and peripheral neuropathy in a large population-based cohort from Pinggu, China.METHODS: A cross-sectional, randomly selected, population-based survey of participants from Pinggu, China was performed. Metabolic phenotyping and neuropathy...

Cite
Callaghan BC, Gao L, Li Y, et al. Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Ann Clin Transl Neurol. 2018;5(4):397-405doi: 10.1002/acn3.531.
Callaghan, B. C., Gao, L., Li, Y., Zhou, X., Reynolds, E., Banerjee, M., Pop-Busui, R., Feldman, E. L., & Ji, L. (2018). Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Annals of clinical and translational neurology, 5(4), 397-405. https://doi.org/10.1002/acn3.531
Callaghan, Brian C, et al. "Diabetes and obesity are the main metabolic drivers of peripheral neuropathy." Annals of clinical and translational neurology vol. 5,4 (2018): 397-405. doi: https://doi.org/10.1002/acn3.531
Callaghan BC, Gao L, Li Y, Zhou X, Reynolds E, Banerjee M, Pop-Busui R, Feldman EL, Ji L. Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Ann Clin Transl Neurol. 2018 Feb 14;5(4):397-405. doi: 10.1002/acn3.531. eCollection 2018 Apr. PMID: 29687018; PMCID: PMC5899909.
Copy Download .nbib Format: NLM
Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D).

Journal of diabetes and its complications

Ang L, Kidwell KM, Dillon B, Reiss J, Fang F, Leone V, Mizokami-Stout K, Pop-Busui R.
PMID: 34024686
J Diabetes Complications. 2021 Aug;35(8):107949. doi: 10.1016/j.jdiacomp.2021.107949. Epub 2021 May 15.

AIMS: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce blood pressure without compensatory heart rate elevation, possibly by modulating sympathetic/parasympathetic activity. This may contribute to their cardiovascular benefits in type 2 diabetes (T2D). We evaluated the effects of dapagliflozin (DAPA) on measures...

Cite
Ang L, Kidwell KM, Dillon B, et al. Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D). J Diabetes Complications. 2021;35(8):107949doi: 10.1016/j.jdiacomp.2021.107949.
Ang, L., Kidwell, K. M., Dillon, B., Reiss, J., Fang, F., Leone, V., Mizokami-Stout, K., & Pop-Busui, R. (2021). Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D). Journal of diabetes and its complications, 35(8), 107949. https://doi.org/10.1016/j.jdiacomp.2021.107949
Ang, Lynn, et al. "Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D)." Journal of diabetes and its complications vol. 35,8 (2021): 107949. doi: https://doi.org/10.1016/j.jdiacomp.2021.107949
Ang L, Kidwell KM, Dillon B, Reiss J, Fang F, Leone V, Mizokami-Stout K, Pop-Busui R. Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D). J Diabetes Complications. 2021 Aug;35(8):107949. doi: 10.1016/j.jdiacomp.2021.107949. Epub 2021 May 15. PMID: 34024686.
Copy Download .nbib Format: NLM
Urine glycoprotein profile reveals novel markers for chronic kidney disease.

International journal of proteomics

Vivekanandan-Giri A, Slocum JL, Buller CL, Basrur V, Ju W, Pop-Busui R, Lubman DM, Kretzler M, Pennathur S.
PMID: 22091387
Int J Proteomics. 2011;2011:214715. doi: 10.1155/2011/214715. Epub 2011 Oct 10.

Chronic kidney disease (CKD) is a significant public health problem, and progression to end-stage renal disease leads to dramatic increases in morbidity and mortality. The mechanisms underlying progression of disease are poorly defined, and current noninvasive markers incompletely correlate...

Cite
Vivekanandan-Giri A, Slocum JL, Buller CL, et al. Urine glycoprotein profile reveals novel markers for chronic kidney disease. Int J Proteomics. 2011;2011:214715doi: 10.1155/2011/214715.
Vivekanandan-Giri, A., Slocum, J. L., Buller, C. L., Basrur, V., Ju, W., Pop-Busui, R., Lubman, D. M., Kretzler, M., & Pennathur, S. (2011). Urine glycoprotein profile reveals novel markers for chronic kidney disease. International journal of proteomics, 2011214715. https://doi.org/10.1155/2011/214715
Vivekanandan-Giri, Anuradha, et al. "Urine glycoprotein profile reveals novel markers for chronic kidney disease." International journal of proteomics vol. 2011 (2011): 214715. doi: https://doi.org/10.1155/2011/214715
Vivekanandan-Giri A, Slocum JL, Buller CL, Basrur V, Ju W, Pop-Busui R, Lubman DM, Kretzler M, Pennathur S. Urine glycoprotein profile reveals novel markers for chronic kidney disease. Int J Proteomics. 2011;2011:214715. doi: 10.1155/2011/214715. Epub 2011 Oct 10. PMID: 22091387; PMCID: PMC3196258.
Copy Download .nbib Format: NLM
Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19.

Journal of the American Heart Association

Pan M, Vasbinder A, Anderson E, Catalan T, Shadid HR, Berlin H, Padalia K, O'Hayer P, Meloche C, Azam TU, Khaleel I, Michaud E, Blakely P, Bitar A, Huang Y, Zhao L, Pop-Busui R, Loosen SH, Chalkias A, Tacke F, Giamarellos-Bourboulis EJ, Reiser J, Eugen-Olsen J, Hayek SS.
PMID: 34889102
J Am Heart Assoc. 2021 Dec 21;10(24):e023535. doi: 10.1161/JAHA.121.023535. Epub 2021 Dec 10.

Background Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARB) is thought to affect COVID-19 through modulating levels of angiotensin-converting enzyme 2, the cell entry receptor for SARS-CoV2. We sought to assess the association between ACEi/ARB, biomarkers of...

Cite
Pan M, Vasbinder A, Anderson E, et al. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19. J Am Heart Assoc. 2021;10(24):e023535doi: 10.1161/JAHA.121.023535.
Pan, M., Vasbinder, A., Anderson, E., Catalan, T., Shadid, H. R., Berlin, H., Padalia, K., O'Hayer, P., Meloche, C., Azam, T. U., Khaleel, I., Michaud, E., Blakely, P., Bitar, A., Huang, Y., Zhao, L., Pop-Busui, R., Loosen, S. H., Chalkias, A., Tacke, F., Giamarellos-Bourboulis, E. J., Reiser, J., Eugen-Olsen, J., Hayek, S. S. (2021). Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19. Journal of the American Heart Association, 10(24), e023535. https://doi.org/10.1161/JAHA.121.023535
Pan, Michael, et al. "Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19." Journal of the American Heart Association vol. 10,24 (2021): e023535. doi: https://doi.org/10.1161/JAHA.121.023535
Pan M, Vasbinder A, Anderson E, Catalan T, Shadid HR, Berlin H, Padalia K, O'Hayer P, Meloche C, Azam TU, Khaleel I, Michaud E, Blakely P, Bitar A, Huang Y, Zhao L, Pop-Busui R, Loosen SH, Chalkias A, Tacke F, Giamarellos-Bourboulis EJ, Reiser J, Eugen-Olsen J, Hayek SS. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19. J Am Heart Assoc. 2021 Dec 21;10(24):e023535. doi: 10.1161/JAHA.121.023535. Epub 2021 Dec 10. PMID: 34889102.
Copy Download .nbib Format: NLM
The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin.

Diabetes care

Aleppo G, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, Pop-Busui R, Philis-Tsimikas A, Bao S, Umpierrez G, Davis G, Kruger D, Bhargava A, Young L, Buse JB, McGill JB, Martens T, Nguyen QT, Orozco I, Biggs W, Lucas KJ, Polonsky WH, Price D, Bergenstal RM.
PMID: 34588210
Diabetes Care. 2021 Dec;44(12):2729-2737. doi: 10.2337/dc21-1304. Epub 2021 Sep 29.

OBJECTIVE: To explore the effect of discontinuing continuous glucose monitoring (CGM) after 8 months of CGM use in adults with type 2 diabetes treated with basal without bolus insulin.RESEARCH DESIGN AND METHODS: This multicenter trial had an initial randomization...

Cite
Aleppo G, Beck RW, Bailey R, et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care. 2021;44(12):2729-2737doi: 10.2337/dc21-1304.
Aleppo, G., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., Davis, G., Kruger, D., Bhargava, A., Young, L., Buse, J. B., McGill, J. B., Martens, T., Nguyen, Q. T., Orozco, I., Biggs, W., Lucas, K. J., Polonsky, W. H., Price, D., Bergenstal, R. M. (2021). The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes care, 44(12), 2729-2737. https://doi.org/10.2337/dc21-1304
Aleppo, Grazia, et al. "The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin." Diabetes care vol. 44,12 (2021): 2729-2737. doi: https://doi.org/10.2337/dc21-1304
Aleppo G, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, Pop-Busui R, Philis-Tsimikas A, Bao S, Umpierrez G, Davis G, Kruger D, Bhargava A, Young L, Buse JB, McGill JB, Martens T, Nguyen QT, Orozco I, Biggs W, Lucas KJ, Polonsky WH, Price D, Bergenstal RM. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care. 2021 Dec;44(12):2729-2737. doi: 10.2337/dc21-1304. Epub 2021 Sep 29. PMID: 34588210.
Copy Download .nbib Format: NLM
Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.

Diabetes technology & therapeutics

Carlson AL, Sherr JL, Shulman DI, Garg SK, Pop-Busui R, Bode BW, Lilenquist DR, Brazg RL, Kaiserman KB, Kipnes MS, Thrasher JR, Reed JHC, Slover RH, Philis-Tsimikas A, Christiansen M, Grosman B, Roy A, Vella M, Jonkers RAM, Chen X, Shin J, Cordero TL, Lee SW, Rhinehart AS, Vigersky RA.
PMID: 34694909
Diabetes Technol Ther. 2021 Nov 16; doi: 10.1089/dia.2021.0319. Epub 2021 Nov 16.

No abstract available.

Cite
Carlson AL, Sherr JL, Shulman DI, et al. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2021;doi: 10.1089/dia.2021.0319.
Carlson, A. L., Sherr, J. L., Shulman, D. I., Garg, S. K., Pop-Busui, R., Bode, B. W., Lilenquist, D. R., Brazg, R. L., Kaiserman, K. B., Kipnes, M. S., Thrasher, J. R., Reed, J. H. C., Slover, R. H., Philis-Tsimikas, A., Christiansen, M., Grosman, B., Roy, A., Vella, M., Jonkers, R. A. M., Chen, X., Shin, J., Cordero, T. L., Lee, S. W., Rhinehart, A. S., & Vigersky, R. A. (2021). Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes technology & therapeutics, . https://doi.org/10.1089/dia.2021.0319
Carlson, Anders L, et al. "Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes." Diabetes technology & therapeutics vol. (2021). doi: https://doi.org/10.1089/dia.2021.0319
Carlson AL, Sherr JL, Shulman DI, Garg SK, Pop-Busui R, Bode BW, Lilenquist DR, Brazg RL, Kaiserman KB, Kipnes MS, Thrasher JR, Reed JHC, Slover RH, Philis-Tsimikas A, Christiansen M, Grosman B, Roy A, Vella M, Jonkers RAM, Chen X, Shin J, Cordero TL, Lee SW, Rhinehart AS, Vigersky RA. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2021 Nov 16; doi: 10.1089/dia.2021.0319. Epub 2021 Nov 16. PMID: 34694909.
Copy Download .nbib Format: NLM
The cross-sectional association of renal dysfunction with tests of cognition in middle-aged adults with early type 2 diabetes: The GRADE Study.

Journal of diabetes and its complications

Barzilay JI, Younes N, Pop-Busui R, Florez H, Seaquist E, Falck-Ytter C, Luchsinger JA.
PMID: 33288412
J Diabetes Complications. 2021 Mar;35(3):107805. doi: 10.1016/j.jdiacomp.2020.107805. Epub 2020 Nov 26.

OBJECTIVE: The association of renal dysfunction with tests of cognition in type 2 diabetes has been examined in individuals with moderate and advanced renal disease. Here we examine the association of renal dysfunction with tests of cognition in a...

Cite
Barzilay JI, Younes N, Pop-Busui R, et al. The cross-sectional association of renal dysfunction with tests of cognition in middle-aged adults with early type 2 diabetes: The GRADE Study. J Diabetes Complications. 2020;35(3):107805doi: 10.1016/j.jdiacomp.2020.107805.
Barzilay, J. I., Younes, N., Pop-Busui, R., Florez, H., Seaquist, E., Falck-Ytter, C., Luchsinger, J. A. (2021). The cross-sectional association of renal dysfunction with tests of cognition in middle-aged adults with early type 2 diabetes: The GRADE Study. Journal of diabetes and its complications, 35(3), 107805. https://doi.org/10.1016/j.jdiacomp.2020.107805
Barzilay, Joshua I, et al. "The cross-sectional association of renal dysfunction with tests of cognition in middle-aged adults with early type 2 diabetes: The GRADE Study." Journal of diabetes and its complications vol. 35,3 (2021): 107805. doi: https://doi.org/10.1016/j.jdiacomp.2020.107805
Barzilay JI, Younes N, Pop-Busui R, Florez H, Seaquist E, Falck-Ytter C, Luchsinger JA. The cross-sectional association of renal dysfunction with tests of cognition in middle-aged adults with early type 2 diabetes: The GRADE Study. J Diabetes Complications. 2021 Mar;35(3):107805. doi: 10.1016/j.jdiacomp.2020.107805. Epub 2020 Nov 26. PMID: 33288412; PMCID: PMC7870547.
Copy Download .nbib Format: NLM
Showing 37 to 46 of 46 entries